• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
GeoVax Labs, Inc. (GOVX) - Financial and Strategic SWOT Analysis Review - Product Image

GeoVax Labs, Inc. (GOVX) - Financial and Strategic SWOT Analysis Review

  • ID: 1292024
  • April 2014
  • 45 pages
  • GlobalData

FEATURED COMPANIES

  • AVI BioPharma Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • MORE

GeoVax Labs, Inc. (GOVX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A READ MORE >

FEATURED COMPANIES

  • AVI BioPharma Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • MORE

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 - About the Company
GeoVax Labs, Inc. - Key Facts
GeoVax Labs, Inc. - Key Employees
GeoVax Labs, Inc. - Key Employee Biographies
GeoVax Labs, Inc. - Major Products and Services
GeoVax Labs, Inc. - Pharmaceutical Pipeline Products Data
GeoVax Labs, Inc., Pipeline Products by Therapy Area
GeoVax Labs, Inc., Pipeline Products by Development Phase
GeoVax Labs, Inc. - History
GeoVax Labs, Inc. - Company Statement
GeoVax Labs, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
GeoVax Labs, Inc. - Business Description
GeoVax Labs, Inc. - Corporate Strategy
GeoVax Labs, Inc. - SWOT Analysis
SWOT Analysis - Overview
GeoVax Labs, Inc. - Strengths
Strength - Unique Technologies
Strength - Strong Intellectual Property
Strength - Sturdy R&D Activities
GeoVax Labs, Inc. - Weaknesses
Weakness - History of Losses
GeoVax Labs, Inc. - Opportunities
Opportunity - Entry into Therapeutic Treatment
Opportunity - Market Potential: HIV
Opportunity - Emerging Markets
GeoVax Labs, Inc. - Threats
Threat - Uncertain R&D Outcomes
Threat - Tightening of FDA’s Regulatory Oversight
Threat - Intense Competition
GeoVax Labs, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
GeoVax Labs, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
GeoVax Labs, Inc., Recent Developments
Mar 19, 2014: GeoVax Announces Publication of Repeat Challenge Preclinical Trial in the Journal of Virology
Mar 05, 2014: GeoVax Labs Reports 2013 Financial Results and Provides Corporate Update
Jan 28, 2014: GeoVax Presents at the Phacilitate Vaccine Forum 2014
Nov 22, 2013: GeoVax Appoints Dr. Arban Domi as Director, Vector Development
Nov 18, 2013: GeoVax chief scientific officer lectures at the Texas A&M Health Science Center College of Medicine
Nov 12, 2013: GeoVax Reports 2013 Third Quarter Financial Results
Aug 12, 2013: GeoVax Reports Financial Results for the Second Quarter and First Half 2013 and Provides Clinical Development Update
Aug 01, 2013: GeoVax Awarded Small Business Innovative Research Grant From National Institutes of Health
May 01, 2013: GeoVax Labs Reports Q1 2013 Results
Mar 11, 2013: GeoVax Labs Reports 2012 Results
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
GeoVax Labs, Inc., Key Facts
GeoVax Labs, Inc., Key Employees
GeoVax Labs, Inc., Key Employee Biographies
GeoVax Labs, Inc., Major Products and Services
GeoVax Labs, Inc., Number of Pipeline Products by Therapy Area
GeoVax Labs, Inc., Number of Pipeline Products by Development Stage
GeoVax Labs, Inc., Pipeline Products By Therapy Area and Development Phase
GeoVax Labs, Inc., History
GeoVax Labs, Inc., Subsidiaries
GeoVax Labs, Inc., Key Competitors
GeoVax Labs, Inc., Ratios based on current share price
GeoVax Labs, Inc., Annual Ratios
GeoVax Labs, Inc., Interim Ratios
GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
GeoVax Labs, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
GeoVax Labs, Inc., Pipeline Products by Therapy Area
GeoVax Labs, Inc., Pipeline Products by Development Phase
GeoVax Labs, Inc., Performance Chart (2008 - 2012)
GeoVax Labs, Inc., Ratio Charts
GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
GeoVax Labs, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014

European Vaccine Initiative
U.S. Military HIV Research Program
NIH AIDS Clinical Trials Information Service
GlaxoSmithKline AG
sanofi-aventis AB
Merck & Co., Inc.
Novartis AG
Sanofi
GlaxoSmithKline plc
Gilead Sciences, Inc.
AVI BioPharma Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS